Ten billion ophthalmic drug market, these enterprises are making efforts

According to the analysis of pharmaceutical net market, it is understood that the incidence rate of eye diseases is increasing continuously due to the aging of population, the widespread use of electronic products and improper use of eye The incidence rate of eye diseases such as eye infection, conjunctivitis, macular degeneration and dry eye has increased significantly It is reported that as of 2017, there are about 550 million myopia, 10 million glaucoma, 6 million cataracts and 11.6 million patients with fundus neovascularization disease in China, and ametropia, glaucoma, cataracts and other blinding diseases are also gradually showing a younger trend However, it is the accumulation of these factors that brings great opportunities to the ophthalmic industry in China Data shows that from 2013 to 2017, China's eye market scale increased from 46.7 billion yuan to 86.6 billion yuan, with an average compound growth rate of 16.7% With the incidence rate of eye diseases increasing, ophthalmic treatment technology upgrading and patient's awareness raising, the scale of Ophthalmology market in China is expected to grow at a rate of 14% or so in 2018-2022 years, and the total scale is expected to exceed 100 billion yuan It is understood that ophthalmic dosage forms are mainly eyedrops, eye ointments, injections, gel, eye cavity smear drugs According to the different types of eye diseases, ophthalmic drugs can be divided into anti infection drugs, anti fatigue drugs, cataract drugs, anti glaucoma drugs, anti allergy drugs, lubricants and so on Among them, anti fatigue drugs, anti infection drugs and cataract drugs are the three categories with a large market share, accounting for more than 90% of the total market share At present, many domestic and foreign enterprises are increasing the size of the domestic eye medicine market layout For example, recently, Japan's towering pharmaceutical company announced that it has selected industrial land in Suzhou Industrial Park for the construction of the second pharmaceutical factory of towering Pharmaceutical (China) Co., Ltd It is reported that Tiantian pharmaceutical's tepros was selected as the medical insurance payment product in the medical insurance negotiation in 2019, with a price reduction rate of 72.3% and medical insurance payment price of 74.8 yuan In addition, on November 7, 2019, Hengrui medicine disclosed that it had reached an agreement with novaliq, a German company, to spend a large amount of money to introduce its drugs, cyclosporine TM (0.1% cyclosporine a preparation) and nov03 (perfluorohexyloctane), for the treatment of dry eye It is reported that after the agreement is reached, Hengrui will obtain the rights of clinical development, production and marketing of the two products in China   In addition, on November 5, kangzhe pharmaceutical announced that it would cooperate with SPARC to introduce three ophthalmic products, namely, the ophthalmic emulsion xelpros, the eye drops pdp-716 and sdn-037; on October 22, Zhongsheng pharmaceutical announced that it would sign various strategic cooperation in ophthalmic field with aer Ophthalmology; on July 1, Zhongsheng pharmaceutical announced that it would cooperate with yaomingkangde in the research and development of "zsym011, a new drug for the treatment of diabetic macular edema (DME)" Project Generally speaking, the ophthalmic drug market has a broad prospect However, in the ophthalmic drug market of China, due to the late start of domestic ophthalmic drug enterprises, the relatively weak foundation and technology accumulation, foreign enterprises firmly occupy the leading position in the ophthalmic drug hospital market with strong technical strength and strong brand promotion In the future, in order to occupy more market share in ophthalmic medicine market, domestic enterprises need to catch up with each other and accelerate the pace of innovation and R & D.